A Study of Nivolumab-relatlimab Fixed-dose Combination Versus Regorafenib or TAS-102 in Participants With Later-lines of Metastatic Colorectal Cancer
← catalyst calendarSponsored by Bristol-Myers Squibb (industry) · BMY — their whole pipeline →.
Phase
Phase 3
Status
Terminated
Study type
Interventional
Design
Randomized · None · Treatment
Enrollment
770actual
Sites
139
Countries
Argentina, Australia, Austria +19
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Why the sponsor stopped it
Inability to meet protocol objectives
As filed on the registry record, in the sponsor's own words.
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2022-04-28 | actual | When the study began enrolling |
| Primary completion | 2025-07-14 | actual | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2025-07-14 | actual | The whole study's end, after follow-up |
| First posted | 2022-04-14 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2025-08-13 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Colorectal Neoplasms
Interventions
- Drug: Nivolumab-relatlimab FDC — also filed as BMS-986213
- Drug: Regorafenib — also filed as Stivarga
- Drug: TAS-102 — also filed as Trifluridine/Tipiracil, Lonsurf
Primary outcomes
what the primary-completion date above is the date OFOverall survival (OS) in randomized participants with programmed death-ligand 1 (PD-L1) combined positive score (CPS) ≥ 1
measured Up to 5 years after last participant randomized
OS in all randomized participants
measured Up to 5 years after last participant randomized
Permalink · BMY's whole pipeline · Catalyst calendar · Every registered study · What changed